BioAtla (NASDAQ:BCAB – Get Free Report) released its earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.01), Zacks reports.
BioAtla Stock Performance
BCAB opened at $0.45 on Thursday. The business’s 50-day simple moving average is $0.36 and its 200 day simple moving average is $0.83. The firm has a market capitalization of $26.11 million, a PE ratio of -0.26 and a beta of 1.01. BioAtla has a 52-week low of $0.24 and a 52-week high of $3.42.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “neutral” rating on shares of BioAtla in a research report on Monday, March 31st.
BioAtla Company Profile
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Read More
- Five stocks we like better than BioAtla
- Investing in Travel Stocks Benefits
- Uber’s Earnings Offer Clues on the Stock and Broader Economy
- The Basics of Support and Resistance
- Institutions Skipped the Rally: Where the Money Went
- What is the S&P/TSX Index?
- Survey: America’s Most Inspirational Women Business Leaders [2025]
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
